Validate plasma GFAP as causal biomarker for BBB permeability in early AD

Test whether plasma GFAP distinguishes harmful BBB permeability mechanisms from compensatory states. If true, GFAP-targeted studies should predict therapeutic response.

$400

OPEN

Confidence:

50%

Created: 2026-04-26

Linked Targets (1)

GFAP Glial fibrillary acidic protein 0.41

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (1)

plasma GFAP separates causal from compensatory states in: Blood-brain barrier pe plasma GFAP0.74